Evidence map›Paper›PMID 34791805›Full record

Trial reportThoracic cancer2022

Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.

Xiang Ji, Lisheng Xu, Pengfei Pan, Zhiyun Xu, Aihua Wang, Yu Li

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiang Ji *Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China.
Lisheng Xu *Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China.
Pengfei PanDepartment of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China.ORCID 0000-0002-5983-2288
Zhiyun XuDepartment of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China.
Aihua WangDepartment of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China.
Yu LiDepartment of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China.ORCID 0000-0001-6210-3708
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNCCN guidelines recommend a dose of 100 μg/kg or a fixed dose of 6 mg pegylated recombinant human granulocyte colony-stimulating factor (PEG rhG-CSF) for chemotherapy-induced neutropenia. However, a single dose of 60 μg/kg or 100 μg/kg produced a similar neutrophil response among patients with chemotherapy-induced neutropenia (CIN). Thus, this prospective randomized study was designed to investigate the efficacy of 3 mg PEG rhG-CSF in preventing acute lower respiratory tract infection (ALRTI) after chemotherapy.

methodsPatients with stage IIIB/IVA lung cancer who underwent chemotherapy were randomly divided into a (i) control group, and (ii) treatment group subject to 3 mg PEG rhG-CSF after chemotherapy. Patients in the control group were administered rhG-CSF (5 μg/kg) when decreased absolute neutrophil count (ANC) reached grade 3 of adverse events. The primary outcome was incidence of ALRTI, and the secondary outcomes included ANC, febrile neutropenia (FN), incidence of delayed chemotherapy, infection-related medical expenses and adverse reactions.

resultsCompared with the control group, there was a significant decrease in the incidence of ALRTI (9.6% vs. 24.6%, p < 0.01), FN (1.7% vs. 7.3%, p < 0.001) and neutropenia (8.3% vs. 23.3%, p < 0.01) in the PEG-rhG-CSF group. The incidence of ALRTI was significantly correlated with the grade of CTCAE on ANC. The main adverse reactions of PEG-rhG-CSF were pain and fatigue, among which three cases showed pain of ≥ grade 3. The cost of infection-associated medical expenditure in the treatment group was greatly reduced compared with the control group (p < 0.001).

conclusionsALRTI could well be prevented after prophylactic application of PEG-rhG-CSF (3 mg), and was related to the reduced neutropenia.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsDrug Therapy, CombinationFemaleGranulocyte Colony-Stimulating FactorHumansLung NeoplasmsMaleMiddle AgedNeutropeniaPolyethylene GlycolsProspective StudiesRecombinant ProteinsRespiratory Tract InfectionsGranulocyte Colony-Stimulating Factorpegylated granulocyte colony-stimulating factorPolyethylene GlycolsRecombinant Proteinshuman granulocytelung cancerneutropeniapegylated recombinant human granulocyte colony-stimulating factor

Identifiers

PMID34791805
PMCPMC8720626
OpenAlexW3212218503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.